Adaptive Biotechnologies Corporation (ADPT) is a biotechnology company that uses immune-driven medicine to transform the way diseases like cancer, autoimmune conditions, and infectious diseases are diagnosed and treated. Its core technology decodes the adaptive immune system through next-generation sequencing and machine learning.
The company’s flagship products include ClonoSEQ, a diagnostic tool for detecting minimal residual disease in blood cancers, and ImmunoSEQ, a research platform for mapping T-cell and B-cell receptors. Adaptive has also partnered with Microsoft to accelerate the development of its T-cell–based diagnostics, integrating massive datasets with AI for early disease detection and immune response tracking.
As precision medicine and immune profiling become central to modern healthcare, Adaptive is positioned at the forefront of innovation. Its combination of cutting-edge genomics and computational biology puts it in a strong position to lead in immune-based diagnostics. Visit Adaptive Biotechnologies’ website for more details.
